Researchers have discovered that a common plant in Brazil contains the cannabis ingredient cannabidiol (CBD). This discovery creates new opportunities for the production of the well-known substance from alternative sources.

A group of scientists from the Federal University of Rio de Janeiro uncovered CBD in the flowers and fruits of the Tremamicranthablume (trema) plant, a common shrub found throughout Brazil. According to lead scientist Rodrigo Moura Neto, the plant, which is sometimes categorized as a weed, is a promising source of CBD.

CBD, recognized for its potential in managing anxiety, chronic pain and epilepsy, stands as a key active component in marijuana, alongside tetrahydrocannabinol (THC), which is responsible for inducing the “high” associated with cannabis use.

While CBD’s medicinal efficacy remains under scientific scrutiny, Neto’s chemical analysis confirmed the presence of CBD in trema while ruling out the existence of THC. This development points to the likelihood of discovering additional sources of CBD, evading the legal constraints tethered to marijuana, which remains prohibited in many regions, including Brazil.

“It presents a legal alternative to marijuana use,” said Neto, highlighting the ubiquitous growth of trema throughout Brazil and emphasizing its potential as a more accessible and cost-effective CBD source. He also noted that CBD had previously been found in a related plant in Thailand.

Additionally, a different study published in May 2023 in the “Nature Plants” Journal revealed that the woolly umbrella, a plant native to South Africa, contained more than a dozen different types of cannabinoids. Despite the plant’s inability to produce CBD or THC, researchers did discover notable concentrations of cannabigerolic acid (CBGA), cannabichromene (CBC) and cannabibigerol (CBG).

Although Neto has not yet formally published his findings, he stated that he intends to broaden the study’s emphasis to include improving trema CBD extraction techniques and evaluating the drug’s efficacy in treating patients for ailments that are currently being treated with medicinal cannabis.

The Brazilian government recently awarded his team a grant of 500,000 real ($104,000) to continue the research, which he predicts will take at least five years to finish.

According to a survey conducted last year by market research company Vantage Market Research, the global market for CBD is currently expected to be worth close to $5 billion. The study also predicted that the industry will likely expand to exceed $47 billion by 2028, primarily due to the substance’s increasing popularity in health and wellness.

These research findings could open up new opportunities for the wider cannabis industry, including established actors such as SNDL Inc. (NASDAQ: SNDL), which could explore diversifying their operations.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Cannabis use, whether for medical or recreational purposes, may have adverse effects due to the presence of harmful fungi contaminating the plants, according to a recent peer-reviewed study. The study, published in the “Frontiers in Microbiology” journal, employed data derived from earlier studies, combined with U.S. and international regulations related to the marijuana industry. The researchers examined various contaminants, including mucor, fusarium, penicillium, aspergillus and other fungi capable of infecting cannabis plants and generating mycotoxins.

The findings showed that specific fungi could induce infections in lung and skin tissues, with such infections being more prevalent when marijuana is smoked compared to when it’s ingested. Cancer patients using marijuana to alleviate nausea and enhance their appetite, along with transplant recipients and individuals with type 1 diabetes or HIV, are particularly susceptible to these infections. Additionally, the findings suggest that individuals involved in cannabis harvesting might be at risk.

Lead author Kimberly Gwinn said, “Cannabis and hemp are relatively new crops, and our comprehension of their interactions with pathogens is in its infancy. Many pathogens produce mycotoxins, which are compounds known to have detrimental effects on human health and are closely monitored in other crops.

“In our review, we provide a comprehensive overview of the current literature regarding mycotoxins in cannabis and hemp products,” she continued. “We also highlight the existing research gaps regarding potential mycotoxin contamination in these crops, drawing from insights gained in other crop systems.”

While cannabis research has predominantly focused on the substance and its medicinal applications, there is an imperative need for a more extensive examination of potential health hazards associated with its consumption, according to the study. The authors noted that the absence of standardized human health-risk assessment methodologies applicable to the emerging hemp and cannabis industries has resulted in fewer studies focused on their risk. Additionally, the diverse array of consumer uses for these substances, including medicinal use by patients with specific medical conditions, presents a unique challenge in evaluating and mitigating the health risks associated with contaminants.

The differing cannabis regulations from state to state, particularly in the United States, also pose a challenge to mitigating risks. Notably, fusarium mycotoxins, a common class of fungal contaminants that result in vomiting when consumed, currently lack regulatory oversight in most states.

In light of these discoveries, the authors strongly advise immunocompromised consumers to opt for products that have undergone sterilization, at least until more comprehensive data becomes available. The study’s authors also recommend further exploration and possible regulatory adjustments to safeguard consumers, particularly those with compromised immune systems.

This risk of consuming tainted cannabis products is the reason why it is better for consumers to access their products from licensed companies, such as SNDL Inc. (NASDAQ: SNDL), as opposed to riskier black-market products, which don’t adhere to specific standards.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Several months after Minnesota Governor Tim Walz signed a recreational cannabis legalization measure into law and nearly two months after the legislation took effect, the state has seen a significant increase in demand for marijuana classes. Minnesota is a relatively late entrant into the recreational cannabis game, but Minnesotans proved that they overwhelmingly supported legalization via a ballot vote, and they are now eager to learn as much as they can about the often-controversial plant.

According to Minnesota Cannabis College president Tanner Berris, demand for marijuana classes across the state is huge as many residents are itching to tap into the recently launched recreational cannabis industry. Berris says the college has been receiving calls every day, every hour from people who would like to become part of the cannabis industry by either opening a cannabis business or getting a job in the nascent industry.

Although the college’s marijuana program isn’t accredited, the nonprofit has been able to expand from its hemp roots to recreational cannabis now that the state has legalized adult-use marijuana. The college’s goal is now to provide support to entrepreneurs interested in joining the cannabis sector and provide them with the training they will need to flourish in the industry. The school will soon start to offer classes on cannabis cultivation, business management, and “budtending” training to people who want to work in retail cannabis stores.

Since Minnesota’s recreational cannabis law won’t allow the launch of retail marijuana dispensaries until 2025 (with the exception of some tribal nations), interested entrepreneurs have plenty of time to learn about cannabis commerce before official sales commence.

In the meantime, state law currently allows Minnesotans to cultivate up to eight cannabis plants at home.

Although the Minnesota Cannabis College began offering cannabis cultivation classes in reaction to home cultivation laws, the nonprofit is more interested in providing business-related cannabis knowledge. Berris says the most surprising thing has been the number of Minnesotans who have expressed interest in launching their own business. This includes people who use cannabis either sporadically or regularly as well as people who don’t use cannabis but are entrepreneurs who noticed a business opportunity in Minnesota’s burgeoning cannabis sector and are looking for industry-specific information before taking the plunge. Berris says all of the cannabis classes at the nonprofit are full.

Minnesotans interested in an online cannabis education certificate can also head to St. Cloud State University for programs that cover cannabis healthcare and medicine, cannabis compliance and risk management, cannabis agriculture and horticulture, and business of cannabis.

This explosive interest in Minnesota could be signaling to entities operating elsewhere, such as SNDL Inc. (NASDAQ: SNDL), that the cannabis industry still has plenty of room for growth, and any policy changes at the federal level will probably take this growth to a whole new level, bringing massive opportunities to sector players.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

When many people contemplate the euphoria induced by marijuana consumption, their thoughts inevitably gravitate toward THC, the plant’s principal psychoactive constituent. However, a recent study lends support to the notion of the “entourage effect,” demonstrating that marijuana products containing a wider variety of natural cannabinoids result in an even more potent psychoactive high than those made from pure THC.

This research used innovative electroencephalogram (EEG) technology, augmented by AI capabilities, to gauge the euphoria that individuals experienced while vaporizing two distinct products. The first was a full-spectrum live rosin with an average concentration of 85% THC, complemented by other natural terpenes and cannabinoids. The second was a high-purity THC oil boasting a potency range of 82% to 85%.

Twenty-eight adults took part in the study, donning EEG headsets created by the marijuana technology company Zentrela. The participants ingested two hits (8 mg) of the first or second product through a vape made by PAX, which also sponsored the research.

Before consuming the products, the participants underwent a baseline reading. Over the ensuing 90 minutes, the EEG observed cerebral activity across eight distinct brain regions. Subsequently, the collected data were translated into psychoactive effect levels (PEL), which are expressed on a standard scale ranging from 0% to 100%. The outcomes unveiled that the full-spectrum live rosin, containing THC along with other terpenes and cannabinoids, exhibited a slightly swifter onset: three minutes. Results showed a potency reading of 20.8% at the outset and even more substantial potencies at the 15-minute peak (40%) and 90-minute mark (30.2%).

On the other hand, the pure THC product exhibited an average onset time of four minutes with an initial potency of 13.5%. At its peak, the potency registered at 19.1%, subsequently declining to 18.1%.

In essence, the study, while yet to undergo peer review or publication in a scientific journal, lends credence to the entourage effect hypothesis. It suggests that cannabis containing a more varied composition of its innate constituents yields a more potent experience. This finding holds significance for patients, as the entourage effect could potentially fortify specific therapeutic applications.

Brian Witlin, PAX’s vice president of product development, stated in a press release, “Consumers seeking psychoactive effects frequently base their choices on THC content, which is somewhat misleading.”

Beyond enhancing consumer awareness, the study’s findings can also empower marijuana companies to devise more targeted products by harnessing data regarding the distinct combinations of cannabinoids that engender diverse effects.

This study isn’t the first to spotlight the comparative advantages of diverse marijuana products. In 2018, a study revealed that patients with epilepsy who utilize plant-based CBD extracts as opposed to refined CBD products have better health results and experience fewer negative side effects.

For companies that sell whole-flower products, such as SNDL Inc. (NASDAQ: SNDL), the study’s findings that the entourage effect triggers more intense experiences for cannabis users makes a case for the continued development of products that leverage the entire spectrum of cannabinoids and other constituents rather than individual compounds.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Srettha Thavisin, Thailand’s newly elected prime minister, has pledged to change the country’s cannabis laws over the next six months to limit their use to medical purposes only. Thailand became the first Asian country to decriminalize marijuana after delisting the plant as a narcotic last year, resulting in a surge of cannabis dispensaries and cafes in major tourist locations such as Pattaya, Chiang Mai and Bangkok.

Currently, Thai law allows adults over the age of 20 to use marijuana inside their homes but not while they are nursing or pregnant. Furthermore, foods containing cannabis extracts are permitted to be served in restaurants with a license.

However, the lack of legislation to govern its usage has resulted in a legal gap in the country. Presently, about 6,000 dispensaries are operating nationwide, offering a range of cannabis products from oil extracts to buds. Thai farmers have also been permitted to cultivate marijuana after registering with the Thai FDA.

Thailand’s new leader, who took office in August, stressed the consensus within the coalition government to amend the law and prohibit recreational use. “The law must undergo a complete overhaul,” Srettha stated. “It needs correction. We can only control it for medical use,” he added, dismissing any compromise for recreational usage.

Srettha is the leader of the Pheu Thai Party, which formed a coalition government with 10 other parties. Prior to the May elections, the coalition advocated for a strict antidrug campaign and pledged to undo the historic cannabis decriminalization policy. The coalition includes the Bhumjaithai Party, led by Anutin Charnvirakul, who remains committed to advancing a parliamentary bill aimed at introducing stricter industry oversight while opposing the reclassification of marijuana as a controlled substance.

Some within the tourism sector have welcomed the move to restrict cannabis usage, citing problems arising from lax industry regulations. Thanet Supornsahasrungsi, group executive director of Sunshine Hotels and Resorts in Pattaya, remarked that most marijuana shops largely cater to recreational users and that there have been reports of marijuana overdoses. He emphasized the importance of stricter regulations to ensure that individuals who need it receive safe medical care.

Supporters of recreational cannabis argue that reclassifying the substance as a narcotic instead of implementing industry regulation, could drive recreational usage into an unregulated underground market, exacerbating control issues. Thailand plays a key role in drug trafficking along the vast Mekong River valley in southeast Asia, often with the assistance of law enforcement agencies. Srettha has committed to eliminating illicit drugs in the nation within a year.

This policy reversal is obviously disturbing to companies that were investing in the industry in anticipation that enabling regulations would be enacted. Even established companies such as SNDL Inc. (NASDAQ: SNDL) would be immensely impacted if any of the markets in which they had advanced plans to expand into suddenly changed course and reestablished prohibitive policies.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Activists in Nebraska have initiated a fundraising campaign to garner support for the inclusion of two medical cannabis legalization proposals on the state’s 2024 ballot. The group, Nebraskans for Medical Cannabis (NMM), has already begun the circulation of petitions and claims to have satisfied signature requirements in two counties by the end of last month.

The recent launch event held in Lincoln aimed to address a significant hurdle faced last year: the loss of vital funding after a major donor’s tragic death in a plane crash.

This is the third attempt by NMM to present the reform proposal to voters, and activists maintain their optimism, believing they will secure the necessary grassroots backing and resources to succeed this time around.

The launch showcased the involvement of various caregivers, patients and activists in medical marijuana advocacy, including key figures such as Crista Eggers, the campaign manager, and Senator Anna Wishart and former Senator Adam Morfeld, both of whom cochair NMM.

The campaign is set to obtain signatures from at least 5% of registered voters in 38 counties by year-end, with two counties already accomplished. To secure a place on the November 2024 ballot, the campaign must collect approximately 87,000 valid signatures from registered voters for each petition, in addition to meeting the county-specific goals, by July 5, 2024.

One of the initiatives seeks to establish safeguards for doctors recommending cannabis and patients purchasing and possessing it, effectively creating qualified immunity. The second initiative plans to establish a state cannabis commission to oversee the registration and regulation of individuals involved in the production, distribution and dispensing of medical cannabis.

Governor Jim Pillen has voiced opposition to marijuana reform, asserting that medical cannabis should only be accessible through FDA-approved processes, citing potential risks to children. In contrast, Eggers, NMM’s campaign manager, is determined to advocate for children such as her son, who suffers from severe seizures and could benefit from medical cannabis.

NMM initially submitted its reform petitions in May, with signature collection starting in July. An earlier campaign secured enough signatures for the 2020 ballot but was invalidated by the state Supreme Court due to a single-subject challenge. Subsequently, the revised petitions fell short due to a lack of funding following the tragic plane crash that claimed a key donor’s life.

Efforts by Nebraska legislators, including Wishart, to enact marijuana reform legislatively have consistently faced hurdles in the conservative legislature. Despite receiving a hearing in the unicameral Judiciary Committee in February, Wishart’s medical marijuana bill did not progress, which she attributed to changes in committee membership. A prior version of the measure faced a filibuster and ultimately stalled in the GOP-controlled legislature.

As many more states and countries work to ease their marijuana regulations, companies such as SNDL Inc. (NASDAQ: SNDL) will have a bigger pool of potential markets into which to expand as they grow their footprints.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

New data from Health Canada has revealed that Australia and Israel were the top buyers of Canada’s medical marijuana exports in 2022. Figures shared through MJBizDaily show that the two nations were the largest markets for Canadian medical cannabis importers amid a surge in cannabis exports from Canada.

Medical cannabis flower exports from the North American nation totaled around 132,200 pounds for fiscal year April 2022 through March 2023 and went up by 48% from the previous fiscal year’s roughly 90,000 pounds. Close to 80% of medical marijuana flower exports from Canada (104,000 pounds) went to Australia and Israel and 16% (21,000 pounds) went to Germany.

Canada has exported 277,000 pounds (126,025 kilograms) of medical marijuana flower for commercial and scientific use since 2017, MJBizDaily reports. The value of Canada’s medical marijuana exports in 2022 also increased by 50% from the fiscal year 2021–2022 to around $118 million. However, while players in the cannabis industry are likely pleased with the increased international demand for their cannabis flower, relying on three nations for the majority of exports puts the Canadian medical marijuana export segment at significant risk.

According to Miguel Martin, the CEO of Edmonton, Canada, cannabis producer Aurora Cannabis, investing in medical marijuana flower exports is a “long-term play.” He noted that export margins are 2.5 times higher than margins in the local recreational marijuana market and are “not declining.”

Although Australia and Israel were both major importers of Canadian medical cannabis flower, Australia imported most of Canada’s cannabis extracts in 2022. Of the 2,388 gallons of medical cannabis extract Canada exported last year, 2,217 gallons went to Australia followed by the Cayman Islands at 845 gallons, and Brazil, Barbados and South Africa at 35 gallons, 27 gallons and 23 gallons respectively.

Cannabis producers in Canada have become increasingly focused on the international market due to higher margins compared to the Canadian market, which is plagued with issues such as oversaturation and oversupply. Additionally, excise taxes levied by Canadian authorities on cannabis products reduce margins for cannabis producers in local markets and incentivize them to seek business partnerships with buyers in other nations.

Thanks to significantly reduced competition in foreign markets such as Israel and Australia, Canadian medical cannabis exporters don’t have to worry about sharing their market with an increasing number of sellers. However, nations such as Denmark and Columbia are becoming increasingly relevant in the global cannabis trade and may soon begin eating into Canada’s market share. Companies such as SNDL Inc. (NASDAQ: SNDL) therefore have to step up their innovativeness even more in order to stay ahead of the competition.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

A recent study published in the “Cancer” Journal explores the potential advantages of utilizing cannabis for children undergoing cancer treatment, a group that contends with various symptoms resulting from the disease and its therapies. However, while promising, further exploration into appropriate dosing and safety is imperative.

Advances in diagnostics, surgery and radiation have elevated survival rates among pediatric cancer patients. Nevertheless, progress brings its own set of issues, including anorexia, pain, vomiting and nausea, which prove challenging to manage. Cannabis derivatives have emerged as a strategy to alleviate these symptoms in young cancer patients. However, its safety, effectiveness and dosing in this demographic remain largely uncharted.

The authors of the study note that “pediatric oncologists remain cautious about cannabis due to the dearth of substantiated evidence affirming its safety and efficacy within this context. There’s an urgency to comprehensively examine the current landscape of cannabinoid application in pediatric cancer, guiding the evolution of clinical trials scrutinizing the impact of diverse cannabis products on safety, dosing, and efficacy for this demographic.”

Researchers from the University of Manitoba undertook a systematic meta-analysis and review to evaluate the body of literature concerning the use of medicinal marijuana for alleviating symptoms in pediatric cancer cases. They drew upon resources such as the Cochrane Library, PsycINFO, Embase and MEDLINE.

A total of 34,611 citations were examined, involving various cannabis strains, quantities, forms, administration methods and indications, as well as clinical and demographic attributes. These citations also encompass documented efficacy outcomes and any resultant unfavorable incidents. From those, 19 studies along with 1,927 participants were considered suitable for the study.

Within these studies, diverse marijuana products emerged as potential solutions for tackling distinct symptoms. Primarily, cannabis demonstrated efficacy in countering chemotherapy-induced vomiting and nausea. The side effects linked to cannabis usage include dry mouth, drowsiness and vertigo. Importantly, none of the studies documented any severe adversities linked to cannabis use in alleviating cancer-related symptoms in pediatric patients.

Lead author Lauren E. Kelly, PhD, acknowledged the challenges in measuring overall advantages due to disparate outcomes and study designs. Kelly noted, “While interventions with active control groups showed the superiority of cannabinoids in countering nausea and vomiting, data scarcity persists concerning cannabinoids’ influence on sleep, mood, pain, and the holistic quality of life.”

The study’s limitations included the count of studies within the review, outcome reporting inconsistencies, and the absence of case-controlled or cohort studies in the analysis.

Kelly emphasized the pivotal importance of conducting more rigorous investigations into the effects of cannabinoids on pediatric cancer patients and sharing such findings with the healthcare sector, patients and parents, given the varying experiences reported by children in terms of benefits and adverse events.

As more information becomes available regarding the therapeutic potential of cannabis for specific groups or demographics of patients, marijuana companies such as SNDL Inc. (NASDAQ: SNDL) could tweak their products in order to avail the most suitable product to address the specific symptoms of those patients.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN